Effect of trimetazidine MR 35 mg on the emergence of choroidal neovascularisation in age-related macular degeneration

Study of the effect of trimetazidine MR 35 mg (2 tabs/day) on the emergence of choroidal neovascularisation in age-related macular degeneration: a multicentre, randomised, double-blind, placebo-controlled, phase III study in 1100 patients treated for 3 to 5 years

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN99532788

Enrollment

1100

Registered

2009-04-23

Start date

1999-03-19

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aged-related macular degeneration Eye Diseases Other retinal disorders

Interventions

Oral administration of trimetazidine 35 mg or placebo during 3 to 5 years.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male and female 2. Caucasian 3. Aged 55 to 83 years with age-related macular degeneration 4. Neovascularisation on the first eye

Exclusion criteria

Exclusion criteria: 1. Cataract 2. Diabetic retinopathy 3. Optical neuropathy 4. Neovascularisation on the studied eye

Design outcomes

Primary

Measure	Time frame
Effect on choroidal neovascularisation evaluated each year.	—

Secondary

Measure	Time frame
1. Effect of the serous drusen evaluated each year 2. Evaluation of pigment epithelium lesion evaluated each year 3. Clinical acceptability of trimetazidine evaluated each 6 months	—

Countries

Belgium, France, Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026